SCHEMBL5066564

SCHEMBL5066564

COc1ccc(-c2[c]nccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 1/20 0.48
KDM4E B2RXH2 5/20 0.45
ALDH1A1 P00352 4/20 0.45
HPGD P15428 2/20 0.45
CCNB2 O95067 1/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
RIPK1 Q13546 1/20 0.43
CCNB3 Q8WWL7 1/20 0.43
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4801302 0.80 LTA4H (0.45) ALDH1A1RIPK1NPC1RAB9ASCN4A
SCHEMBL4590846 0.75 MAPK14 (0.35) ALDH1A1HPGDNPC1RAB9ACYP19A1
SCHEMBL5887656 0.74 MAPT (0.47) KDM4EALDH1A1HPGDCCNB2CDK1
SCHEMBL3819482 0.74 APP (0.50) CLK4KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5797199 0.74 MAPT (0.43) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7974674 0.73 MEN1 (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4909130 0.72
SCHEMBL4462175 0.71 KDM4E (0.30) KDM4ENPC1RAB9ALMNANPSR1
SCHEMBL22261802 0.70 CLK4 (0.48) CLK4KDM4EALDH1A1HPGDCCNB2
SCHEMBL592654 0.69 CA4 (0.44) CLK4KDM4EALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080152640-A1 Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer UNIVERSITATSKLINIKUM MUNSTER (DE) 2008-06-26 US disclosed
CN-1553900-A Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents ��ʱ��ʩ����ҩ��˾ 2004-12-08 CN disclosed
US-5145858-A Antiinflammatory SMITHKLINE BEECHAM CORP. (US) 1992-09-08 US disclosed
US-5002941-A Antiarthritic agents, arachidonic acid metabolism SMITHKLINE BEECHAM CORPORATION (US) 1991-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152640-A1 Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer ABCB1, ABCB11, SLC47A2 CLK4 4807/4885KDM4E 3660/4885ALDH1A1 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.